about
The evolving treatment paradigm in myelofibrosisRibonucleotide reductase metallocofactor: assembly, maintenance and inhibition.The σ2 receptor: a novel protein for the imaging and treatment of cancer.Nucleotide metabolism, oncogene-induced senescence and cancer.Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.Loss of APD1 in yeast confers hydroxyurea sensitivity suppressed by Yap1p transcription factorRad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.Improving cancer therapy by combining cell biological, physical, and molecular targeting strategies.Targeting ribonucleotide reductase for cancer therapy.Re-evaluation of cytostatic therapies for meningiomas in vitro.S-phase checkpoint regulations that preserve replication and chromosome integrity upon dNTP depletion.Resistance to cisplatin-induced cell death conferred by the activity of organic anion transporting polypeptides (OATP) in human melanoma cells.Treatment of Myelofibrosis: Old and New Strategies.Cell Cycle Inhibition To Treat Sleeping SicknessRecycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.A computational method for the identification of new candidate carcinogenic and non-carcinogenic chemicals.
P2860
Q27021968-5D581E81-D537-4627-913E-6F14E35AF865Q33699869-7DDAA341-99C9-4D10-85FF-56755FECC6F3Q33782364-44E4B231-B75A-49FC-9B7C-49168CDAF6EBQ33969333-849D496E-59DF-4EE4-917F-FCC270329D45Q34906454-AAA51413-1BA9-44C4-9772-4F0FDD768507Q34983831-C7D5365A-7BE6-4B7E-926D-EBF712099373Q35141185-065AB774-FD24-43A0-B4FC-6439C88AF5C6Q36563213-9232C7B7-E2E1-455E-BDA5-3B455DA93A4EQ38148222-8DA422C0-14CC-4FCC-B35B-3D00F2F28BD5Q38996146-4594861E-0883-4516-A1CB-0FEA66413162Q39144822-406FC3D0-6494-4179-818A-ABB0DD865617Q39167342-A12D65D5-1A77-4EB6-BE37-B3068CE5DFB2Q39349869-E8E21862-75E6-480A-AAB7-AC04E6E70FACQ41676261-EB2B9F69-5954-41DE-B2F0-0DB5721CBBEBQ47988508-C5CAC8A5-9CD2-48BE-A6E0-CB8223564425Q51608068-5AF67F41-4311-44C9-813C-C397462B6587Q51839738-6B29CBB2-9F09-4A02-B59A-17F107CCD9DC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Hydroxyurea: a key player in cancer chemotherapy.
@en
Hydroxyurea: a key player in cancer chemotherapy.
@nl
type
label
Hydroxyurea: a key player in cancer chemotherapy.
@en
Hydroxyurea: a key player in cancer chemotherapy.
@nl
prefLabel
Hydroxyurea: a key player in cancer chemotherapy.
@en
Hydroxyurea: a key player in cancer chemotherapy.
@nl
P2093
P2860
P356
P1476
Hydroxyurea: a key player in cancer chemotherapy.
@en
P2093
Darpan Kaushik
Kapish Madaan
Tarawanti Verma
P2860
P356
10.1586/ERA.11.175
P577
2012-01-01T00:00:00Z